Kidney Week

Abstract: PUB122

Impact of Once-Weekly Semaglutide on eGFR and Hemoglobin A1c (HbA1c) among Patients with Type 2 Diabetes and CKD: An Observational Study

Session Information

• Publication Only

Category: Diabetic Kidney Disease

• 702 Diabetic Kidney Disease: Clinical

Authors

• Amamoo, James J., Novo Nordisk Inc., Plainsboro, New Jersey, United States

James J. Amamoo, MS, MSc

• Sheth, Sunny T., Novo Nordisk Inc., Plainsboro, New Jersey, United States

Sunny T. Sheth, PharmD, RPh, MBA

• Brady, Brenna L., Merative, Cambridge, Massachusetts, United States

Brenna L. Brady, PhD

• Tran, Anh Thu, Merative, Cambridge, Massachusetts, United States

Anh Thu Tran, PharmD

• Xie, Lin, Novo Nordisk Inc., Plainsboro, New Jersey, United States

Lin Xie, MA, MS

• Noone, Josh, Novo Nordisk Inc., Plainsboro, New Jersey, United States

Josh Noone, PhD

• Mehanna, Sherif, Novo Nordisk Inc., Plainsboro, New Jersey, United States

Sherif Mehanna, MD

• Bakris, George L., University of Chicago Medical Center, Chicago, Illinois, United States

George L. Bakris, MD, MA, FASN

Background

Of ~35 million patients living with type 2 diabetes (T2D) in the US, 30–40% also have CKD, which is associated with increased morbidity and mortality. Therefore, managing comorbidities is of utmost importance. This real-world study assessed the changes in eGFR and HbA_1c in adults with T2D and CKD following initiation of once-weekly (OW) semaglutide subcutaneous injection.

Methods

This exploratory non-interventional, longitudinal, retrospective cohort study included patients aged ≥18 years with evidence of T2D and CKD (eGFR <60 mL/min/1.73 m²) pre-index, newly initiating OW semaglutide (index selection period: January 2018–September 2022) from the Merative™ MarketScan^® Laboratory Database. Other key inclusion criteria included persistence to OW semaglutide of ≥6 months, and no evidence of dialysis or kidney transplant at baseline. The first prescription fill for OW semaglutide served as the index date. Patients were followed over a variable post-period, the end of which was the first of OW semaglutide discontinuation, end of continuous eligibility or end of study data. Change in eGFR and HbA_1c from the last value taken prior to index date were assessed over a variable period for all patients with ≥6 months’ of follow-up and over a fixed 12-month follow-up.

Results

A total of 254 patients qualified for the analyses. Mean (SD) baseline eGFR and HbA_1c were 45.1 (10.5) mL/min/1.73 m² and 7.8 (1.6)%, respectively. The mean (SD) changes in eGFR and HbA_1c values from baseline to post-index were 2.0 (10.9) mL/min/1.73 m² and −1.1 (1.6)%, respectively. In a subgroup of patients with 12 months’ follow-up (n=99), mean (SD) eGFR and HbA_1c at baseline were 45.2 (10.8) mL/min/1.73 m² and 7.5 (1.7)%, respectively. The mean (SD) changes in eGFR and HbA_1c values from baseline to 12 months post-index were 4.5 (12.8) mL/min/1.73 m² and −1.2 (1.5)%, respectively.

Conclusion

In this exploratory real-world study, initiation of OW semaglutide was associated with improvements in both eGFR and HbA_1c in adults with T2D and CKD over 12 months, demonstrating its potential utility in this patient population.

Funding

• Commercial Support – Novo Nordisk Inc.